Tune into the second episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Center for Medicaid and Medicare (CMS) employees Sean Creighton and Tom Kornfield discuss their thoughts on the best ways for health plans to influence CMS decision making, including timing of engagement and critical messaging elements.
Tune into the first episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Centers for Medicare & Medicaid Services (CMS) employees, Sean Creighton and Tom Kornfield, discuss the outlook for Medicare Advantage, factors that will influence growth of the program, and a behind-the-scenes look at CMS policymaking considerations.
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
Join Avalere’s panel of market access and policy experts for a discussion on the growing cell and gene therapy (CGT) pipeline, an in-depth look at the unique opportunities and challenges these novel therapies present, and an overview of the many hurdles stakeholders need to navigate for success.
Tune into the third episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In the final segment, our Market Access and Policy experts take a deeper dive into disparities in kidney care and discuss how various groups are looking to address these gaps.
Tune into the third episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In the final segment, our Market Access and Policy experts take a deeper dive into disparities in kidney care and discuss how various groups are looking to address these gaps.
Join Avalere for a live discussion on key trends in drug pricing, value, and regulatory shifts, and how these trends will impact manufacturers.
Join Avalere’s healthcare policy experts for an analysis of the final rate announcement and a discussion on the future of Medicare Advantage (MA) and potential outcomes for health plans.
Tune into the second episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In this segment, our Market Access and Policy experts take a deeper dive into several of the policy and payment trends in the kidney disease space.
Tune into the second episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In this segment, our Market Access and Policy experts take a deeper dive into several of the policy and payment trends in the kidney disease space.
Tune into the first episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In this segment, our Market Access experts discuss the kidney disease patient population as well as treatment and payment systems this space.
Tune into the first episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In this segment, our Market Access experts discuss the kidney disease patient population as well as treatment and payment systems this space.
Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome leaders from the National Alliance of State & Territorial AIDS Directors (NASTAD) to discuss how HIV state policies have changed in light of advancements in prevention and treatment, and the key to ending the HIV and viral hepatitis epidemics in the US.
Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome leaders from the National Alliance of State & Territorial AIDS Directors (NASTAD) to discuss how HIV state policies have changed in light of advancements in prevention and treatment, and the key to ending the HIV and viral hepatitis epidemics in the US.
Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome Carl Schmid, Executive Director at the HIV + Hepatitis Policy Institute, to discuss how HIV prevention and treatment policy influence broader health policy issues as we commemorate World AIDS Day on December 1.
Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome Carl Schmid, Executive Director at the HIV + Hepatitis Policy Institute, to discuss how HIV prevention and treatment policy influence broader health policy issues as we commemorate World AIDS Day on December 1.
From policy and regulatory changes to COVID-19 and driving customer engagement, the healthcare environment continues to require healthcare stakeholders to adapt their strategies. How will you stay ahead of the trends impacting your business?
Tune into the fifth and final episode of the Avalere Health Essential Voice miniseries focused on Medicare Part D. In this segment, our experts discuss the Center for Medicare & Medicaid Innovation (CMMI) and its strategic direction for the coming year, particularly as it relates to the Part D program.
